CDK5

Across TCGA pan-cancer cohorts, CDK5 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CDK5 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher CDK5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CDK5 expression acts as an unfavorable survival marker.

STAD, COAD, and PRAD are the cancer types where CDK5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	III,IV	0.126	0.635	<.001	24	view →
COAD	OS	Median	All	0.168	0.799	.004	15	view →
PRAD	OS	Median	All	0.125	0.883	<.001	12	view →
SKCM	DFS	Median	All	0.058	0.762	<.001	9	view →
LUAD	OS	Median	All	0.342	0.702	.005	6	view →
BLCA	DFS	Median	All	0.172	0.510	.033	6	view →
THCA	OS	Median	All	0.342	0.955	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CDK5–STAD (OS)

Open the STAD breakdown →